Drotrecogin alpha (activated) in neonatal septic shock

David Frommhold; Alexandra Birle; Otwin Linderkamp; Eugen Zilow; Johannes Pöschl

doi:10.1080/00365540510031412

Drotrecogin alpha (activated) in neonatal septic shock

Scand J Infect Dis. 2005;37(4):306-8. doi: 10.1080/00365540510031412.

Authors

David Frommhold¹, Alexandra Birle, Otwin Linderkamp, Eugen Zilow, Johannes Pöschl

Affiliation

¹ Division of Neonatology, Department of Paediatrics, University of Heidelberg Medical School, Heidelberg, Germany. david_frommhold@med.uni-heidelberg.de

PMID: 15804668
DOI: 10.1080/00365540510031412

Abstract

A 12-d-old neonate suffering from group B streptococcal septic shock was treated with 24 microg/kg/h recombinant human activated protein C [rhAPC, drotrecogin alpha (activated)] for 96 h. The protein C activity increased from 5% to 53% after rhAPC infusion. The patient recovered within 14 d without any adverse effects.

Publication types

Case Reports

MeSH terms

Anti-Infective Agents / therapeutic use*
Humans
Infant, Newborn
Male
Meningitis, Pneumococcal / complications
Protein C / therapeutic use*
Recombinant Proteins / therapeutic use*
Shock, Septic / drug therapy*
Streptococcal Infections / drug therapy*
Streptococcus agalactiae

Substances

Anti-Infective Agents
Protein C
Recombinant Proteins
drotrecogin alfa activated